Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,041 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.
Glossop PA, Lane CA, Price DA, Bunnage ME, Lewthwaite RA, James K, Brown AD, Yeadon M, Perros-Huguet C, Trevethick MA, Clarke NP, Webster R, Jones RM, Burrows JL, Feeder N, Taylor SC, Spence FJ. Glossop PA, et al. Among authors: jones rm. J Med Chem. 2010 Sep 23;53(18):6640-52. doi: 10.1021/jm1005989. J Med Chem. 2010. PMID: 20804199
The discovery of long acting beta2-adrenoreceptor agonists.
Brown AD, Bunnage ME, Glossop PA, James K, Jones R, Lane CA, Lewthwaite RA, Mantell S, Perros-Huguet C, Price DA, Trevethick M, Webster R. Brown AD, et al. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4012-5. doi: 10.1016/j.bmcl.2007.04.081. Epub 2007 Apr 29. Bioorg Med Chem Lett. 2007. PMID: 17498952
Inhaled adenosine A(2A) receptor agonists for the treatment of chronic obstructive pulmonary disease.
Mantell SJ, Stephenson PT, Monaghan SM, Maw GN, Trevethick MA, Yeadon M, Keir RF, Walker DK, Jones RM, Selby MD, Batchelor DV, Rozze S, Chavaroche H, Hobson TJ, Dodd PG, Lemaitre A, Wright KN, Stuart EF. Mantell SJ, et al. Among authors: jones rm. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1284-7. doi: 10.1016/j.bmcl.2008.01.033. Epub 2008 Jan 12. Bioorg Med Chem Lett. 2008. PMID: 18243699
An in situ oxidation strategy towards overcoming hERG affinity.
Pryde DC, Jones R, Middleton DS, Laverty BJ, Fenwick DR, Mason HJ, Corless M, Smith NN. Pryde DC, et al. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6400-4. doi: 10.1016/j.bmcl.2010.09.089. Epub 2010 Sep 21. Bioorg Med Chem Lett. 2010. PMID: 20934332
Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD.
Jones LH, Baldock H, Bunnage ME, Burrows J, Clarke N, Coghlan M, Entwistle D, Fairman D, Feeder N, Fulton C, Hilton L, James K, Jones RM, Kenyon AS, Marshall S, Newman SD, Osborne R, Patel S, Selby MD, Stuart EF, Trevethick MA, Wright KN, Price DA. Jones LH, et al. Among authors: jones rm. Bioorg Med Chem Lett. 2011 May 1;21(9):2759-63. doi: 10.1016/j.bmcl.2010.10.132. Epub 2010 Oct 31. Bioorg Med Chem Lett. 2011. PMID: 21075627
An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).
Stupple PA, Batchelor DV, Corless M, Dorr PK, Ellis D, Fenwick DR, Galan SR, Jones RM, Mason HJ, Middleton DS, Perros M, Perruccio F, Platts MY, Pryde DC, Rodrigues D, Smith NN, Stephenson PT, Webster R, Westby M, Wood A. Stupple PA, et al. Among authors: jones rm. J Med Chem. 2011 Jan 13;54(1):67-77. doi: 10.1021/jm100978n. Epub 2010 Dec 3. J Med Chem. 2011. PMID: 21128663
Design and synthesis of long acting inhaled corticosteroids for the treatment of asthma.
Millan DS, Ballard SA, Chunn S, Dybowski JA, Fulton CK, Glossop PA, Guillabert E, Hewson CA, Jones RM, Lamb DJ, Napier CM, Payne-Cook TA, Renery ER, Selby MD, Tutt MF, Yeadon M. Millan DS, et al. Among authors: jones rm. Bioorg Med Chem Lett. 2011 Oct 1;21(19):5826-30. doi: 10.1016/j.bmcl.2011.07.106. Epub 2011 Aug 11. Bioorg Med Chem Lett. 2011. PMID: 21880489
Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
Mowbray CE, Bell AS, Clarke NP, Collins M, Jones RM, Lane CA, Liu WL, Newman SD, Paradowski M, Schenck EJ, Selby MD, Swain NA, Williams DH. Mowbray CE, et al. Among authors: jones rm. Bioorg Med Chem Lett. 2011 Nov 1;21(21):6596-602. doi: 10.1016/j.bmcl.2011.07.125. Epub 2011 Aug 9. Bioorg Med Chem Lett. 2011. PMID: 21920751
Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structure-activity relationship (SAR).
Masood MA, Selby MD, Bell AS, Mansfield AC, Gardner M, Smith GF, Lane C, Kenyon-Edwards H, Osborne R, Jones RM, Liu WL, Brown CD, Clarke N, Perrucio F, Mowbray CE. Masood MA, et al. Among authors: jones rm. Bioorg Med Chem Lett. 2011 Nov 1;21(21):6591-5. doi: 10.1016/j.bmcl.2011.07.114. Epub 2011 Aug 27. Bioorg Med Chem Lett. 2011. PMID: 21955944
1,041 results